RLAY Stock Surges As Zovegalisib Data Ignite Bullish Targets

Relay Therapeutics Inc. stocks have been trading up by 11.52 percent after promising clinical data fueled bullish investor sentiment.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RLAY

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Early Phase 2 ReInspire data for zovegalisib in vascular anomalies showed a 60% volumetric response rate at 12 weeks, broad symptom relief, and safety supportive of long‑term dosing, with expansion cohorts now open.
After the clinical update, RLAY shares ripped 9–11% in premarket trading and closed up about 8.6% to $13.14 in the latest regular session, signaling strong momentum‑driven interest.
Barclays lifted its RLAY price target to $27 from $21, flagging zovegalisib as a potential best‑in‑class therapy in a roughly $6B vascular anomalies market with limited competition and a possible accelerated approval path.
JonesResearch upgraded RLAY to Buy from Hold and raised its target to $20, doubling its modeled probability of success for zovegalisib in vascular malformations from 20% to 40% on the new data.
To fund its expanding pipeline, Relay Therapeutics launched a major equity offering at $12.00 per share, aiming to raise roughly $175–$275M, which pressured RLAY about 4.1% after hours but extends the clinical runway.

Live Update At 12:33:23 EDT: On Thursday, May 21, 2026 Relay Therapeutics Inc. stock [NASDAQ: RLAY] is trending up by 11.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Relay Therapeutics, trading as RLAY, is acting like a classic catalyst biotech: ugly P&L today, but a story traders chase for future potential. Revenue is tiny at about $15.4M, yet the gross margin is 100%, which tells you current income is likely from deals, not a commercial franchise. Profitability ratios are deep in the red, with operating and net margins around negative 1,800%–3,000%. That is normal territory for a clinical‑stage name burning cash to advance trials.

The latest quarterly numbers show an operating cash outflow of about $51.1M and a net loss of roughly $73.3M, or about -$0.41 per share. On the flip side, RLAY carries minimal debt and heavy liquidity: a current ratio near 22.6 and roughly $204.6M in cash and equivalents, before factoring in the new raise. That balance sheet matters for traders because it lowers near‑term financing risk.

More Breaking News

On the chart, RLAY has broken out from a tight $12–$13 range to close at $14.52, with volatility and volume ramping. Intraday action shows a spike to $15.45 at the open and then a controlled fade, a pattern of profit‑taking after a news‑driven gap. For active traders, this is a textbook “hot catalyst plus offering overhang” setup.

Why Traders Are Watching RLAY Now

RLAY has grabbed traders’ attention because the zovegalisib story just shifted from “interesting science” to “real commercial shot.” In the Phase 2 ReInspire trial for vascular anomalies, Relay Therapeutics reported a 60% volumetric response rate at 12 weeks. That means most evaluable patients saw measurable shrinkage in lesion volume. Add broad symptom improvement and a safety profile that looks suitable for chronic dosing, and you have the ingredients of a potential long‑duration therapy.

The market reacted immediately. Multiple outlets flagged RLAY ripping more than 9–11% premarket once those zovegalisib data hit, and the stock pushed roughly 8.6% higher to $13.14 in regular hours on 2026/05/19. That surge was not just day‑trader noise. It lined up with a wave of Street reratings.

Barclays raised its RLAY target to $27, reiterating an Overweight call and pointing to a roughly $6B market opportunity in vascular anomalies with limited competition and a possible accelerated approval route. Citizens followed with a target hike to $21, emphasizing that zovegalisib looks more tolerable than Alpelisib and could tap a larger addressable pool. JonesResearch upgraded RLAY to Buy and bumped its target to $20, after doubling its probability‑of‑success estimate for vascular malformations to 40%.

Traders also like that RLAY is not a one‑trick pony. Zovegalisib, a PI3Kα mutant‑selective inhibitor, is being pushed not only in rare PIK3CA‑driven vascular anomalies but also in a Phase 3 program in PI3Kα‑mutated HR+/HER2‑ metastatic breast cancer. That “pipeline‑in‑a‑drug” angle creates multiple catalyst shots over the next couple of years, which is exactly the type of story momentum traders hunt.

The main rub is dilution. Relay Therapeutics moved quickly to capitalize on the rally, announcing an underwritten offering of about 22.9M shares at $12.00, with an option for another 3.44M shares. Depending on full exercise, RLAY expects roughly $175–$275M in gross proceeds. The stock slipped about 4.1% after hours on that headline, showing how sensitive short‑term traders are to supply hitting the tape. But structurally, more cash means more runway to drive zovegalisib through Phase 3 and expand the broader precision oncology and genetic disease pipeline.

Conclusion

For active traders, RLAY is the kind of biotech story that rewards preparation. Strong early Phase 2 data for zovegalisib in vascular anomalies, a 60% response rate, and supportive safety turned Relay Therapeutics from a slow‑burn R&D story into a momentum name. The stock’s jump from the low‑teens into the mid‑teens, combined with new Street targets at $20–$27, shows how quickly sentiment can reset when clinical risk comes down.

At the same time, the fundamentals still scream “development‑stage.” RLAY is burning over $50M in operating cash per quarter, posting steep losses, and trading at a rich price‑to‑sales multiple above 200. The large follow‑on offering at $12.00 adds dilution but also likely extends the cash runway well beyond the next wave of data. That tension—near‑term pressure versus long‑term optionality—is what shapes the trading range from here. For many short‑term traders, that’s exactly where discipline matters most. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” Keeping that trading mindset in focus can help frame how to react when RLAY’s volatility spikes around catalysts.

Traders watching RLAY should track three things: follow‑through on the current breakout, updates from the vascular anomalies expansion cohorts, and any signals from the ongoing Phase 3 breast cancer program. As Tim Sykes loves to remind his students, “Patterns repeat, but only for traders who study them relentlessly.” RLAY is now a live case study in how clinical catalysts, analyst upgrades, and financings collide on the chart—valuable education for anyone trading biotech momentum.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!